Reporting to: Chief Development Officer

Qualified candidates should email resume / CV to Recruiting@Nodthera.com

The Company

NodThera is a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases. Our focus is on developing a new class of potent, highly selective, and brain-penetrant NLRP3 inflammasome inhibitors. We have three therapeutic areas of focus- cardiometabolism, neuroinflammation, and peripheral inflammation. Of these, cardiometabolism is of highest priority as we advance rapidly through phase 2 into phase 3.

Unlike traditional approaches that block individual downstream cytokines, NodThera’s small molecules address the upstream catalyst of inflammation. With our lead candidate, NT-0796, we are uniquely positioned to address the “missing link” in cardiometabolic health: hypothalamic and systemic inflammation. Our recent data demonstrates that by resetting the body’s metabolic set-point and reducing markers like hsCRP, we can deliver cardiovascular risk reduction that rivals other mechanisms with the additional potential of metabolic benefits. To learn more about Nodthera see our website: https://www.nodthera.com/

The Role

We are looking to hire a Director of Clinical Program and Portfolio Management to join our team to manage multiple clinical stage programs. In this role, S/he will be an orchestrator, responsible for the integration of clinical trial execution with the company’s broader strategic objectives. Working directly with the CMO, CDO, as well as medical, regulatory and quality teams, S/he will drive the clinical development roadmap, optimize resource allocation across the portfolio, and serve as a cross-functional bridge between Clinical, Medical, Regulatory and Executive Leadership.

In this role, you will have a seat at the table where the “big picture” is painted. You won’t just follow a protocol; you will help refine the strategy that defines it.

Key Responsibilities

1. Strategic Alignment & CMO Support

• Clinical Roadmap Architecture: Partner with the CMO, CDO and broader leadership to iterate the Clinical Development Plan (CDP) and translate into actionable, multi-year project milestones.
• Executive Reporting: Synthesize complex clinical data and trial progress into high-level briefings for the Board of Directors, investors, and Scientific Advisory Boards.
• Portfolio Prioritization: Assist the CMO/CDO in evaluating trade-offs between opportunities, ensuring that capital and human resources are directed toward those with the highest-value.

2. Clinical Operations & Trial Oversight

• End-to-End Project Management: Manage the planning, execution, and logistics for end of study readout of Phase I-III trials, ensuring they remain on time, within budget, and in full compliance with GCP/ICH guidelines.
• CRO & Vendor Engagement: Assist in selecting and managing partners based on long-term capability rather than just individual trial needs and build and nurture key relationships.
• Risk Mitigation: Proactively identify “critical path” risks (e.g., recruitment bottlenecks, supply chain shifts) and develop contingency strategies before they impact the company’s goals.

3. Team Orchestration

• Internal Liaison: Act as the “connective tissue” between Clinical, CMC (Manufacturing), Regulatory, and Finance to ensure no silos exist that could delay a filing or a data readout.
• Budgetary Stewardship: Manage clinical budgets with a strategic lens, identifying opportunities for cost-efficiency without sacrificing data integrity or patient safety. Work with Finance to implement and track program budget and forecasts.

Requirements

• Master’s or PhD in (Life) Sciences; PMP certification or MBA is a significant plus.
• A minimum of 5 years in biotech/pharma focused on managing clinical stage programs (Phase 1-3)
• Experience working in a biotech preferred
• Understanding of the drug development lifecycle and regulatory landscape (FDA/EMA), with learning agility to fill the gaps.
• Experience with Veeva would be a plus
• Ability to understand a P&L, burn rates, and how clinical delays affect company valuation.
• Exceptional “upward” communication skills; the ability to challenge the CMO and broader leadership constructively.